Helen Swaisland

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers

Peter C.C. Fong, David S. Boss, Timothy A. Yap et al. · New England Journal of Medicine · 2009 · 3.6K citations · Full text

Medicine, Oncology, Pharmacology +17

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types

José Baselga, Danny Rischin, Malcolm Ranson et al. · Journal of Clinical Oncology · 2002 · 831 citations

Medicine, Oncology, Pharmacology +16

ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial

Malcolm Ranson, Lisa A. Hammond, D. K. Ferry et al. · Journal of Clinical Oncology · 2002 · 763 citations

Medicine, Oncology, Pharmacology +14

Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial

Roy S. Herbst, Anne‐Marie Maddox, Mace L. Rothenberg et al. · Journal of Clinical Oncology · 2002 · 578 citations

Medicine, Oncology, Pharmacology +17

Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors

Kazuhiko Nakagawa, Tomohiro Tamura, Shunichi Negoro et al. · Annals of Oncology · 2003 · 275 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +12